Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To assess safety of Phosphatidylcholine paste 600 mg (ESSENTIALE® paste) oral 3 times a day
for 12 weeks in patients with gastrointestinal symptoms in acute and chronic liver diseases.
Secondary Objectives:
To assess effectiveness on symptomatic improvement in patients with gastrointestinal symptoms
in acute and chronic liver diseases.
To monitor compliance.